Analysis: Zoetis Inc.

US:ZTS

Why is Zoetis Inc. stock rising?

  • Expected U.S. approval of long-acting Cytopoint in 2026
  • Full international launches and subsequent expansion of Lenivia and Portela osteoarthritis products
  • Commercial validation of Vetscan OmniMax diagnostics platform expected by end-2026

Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Zoetis Inc. and 4,900+ companies.

Sign in
5-day free pass. No card required.